Here are the results from the online survey I urge CHers to take 30 days after starting the anti-inflammatory regimen, with results of their 25(OH)D3 labs in hand. The following chart illustrates days to a favorable response from start of regimen. As you can see, this can happen rapidly.
For the purpose of this study, I set the Favorable Response = at least a 70% reduction in CH frequency by at least 70% of the CHers starting it. I just checked the latest survey download from two days ago. After 9 years running, survey data from 340 CHers indicate 82% of CHers starting this regimen experience an 82% reduction in CH frequency in the first 30 days and 52% of CHers starting this regimen experience a lasting cessation of their CH symptoms.
Another interesting tidbit. Since I began suggesting CHers switch to the Bio-Tech D3-50 50,000 IU water soluble vitamin D3 in June of 2018, the efficacy figures for 2019 and 2020 have jumped to 88.9% of CHers starting this regimen in 2019-2020 achieving a mean 80% reduction in the frequency of their CH in the first 30 days. Moreover, 66.7% of CHers starting this regimen in this same time frame report a lasting CH pain free response in the first 30 days. That's huge!
Thank all of you who started this regimen then took the time to take the online survey. You've all made these results possible so this is really your study. I'll also add, the data from this study was so compelling, it resulted in the planned gold standard RCT based on this regimen developed by Dr. Mark Burish, MD, PhD, Director Will Erwin Headache Research Center, UT Houston. It's scheduled to start early next year. When it publishes with the results I expect, you'll have helped CHers all over the world. Well done!
Take care,
V/R. Batch